Cell Cycle Checkpoint Kinase and Drug Resistance of Lung Cancer

• Main Authors: Zhiyin KE, Ailing LIANG, Yongjun LIU
• Format: Article
• Language: zho
• Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2021-04-01
• Series: Chinese Journal of Lung Cancer
• Subjects: cell cycle checkpoint kinase; lung neoplasms; drug resistance
• Online Access: http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.09

Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death. Although great progress has been made in chemotherapy, radiotherapy and targeted therapy, the emergence of acquired drug resistance hinders the efficacy of clinical treatment. Studies have shown that tumor is a class of diseases with damaged cell cycle regulation mechanism, in which checkpoint kinase (Chk) plays a core role, Chk1 and Chk2 are very important protein kinases in the checkpoint. In recent years, it has been found that the regulation of Chk1 and Chk2 plays an important role in the clinical treatment and drug resistance mechanism of lung cancer. This article reviews the mechanism of cell cycle checkpoint kinase and drug resistance of lung cancer, and expounds the effective therapeutic targets and methods of lung cancer.